KPV

KPV is a tripeptide consisting of lysine-proline-valine, derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (α-MSH). This short peptide exhibits potent anti-inflammatory properties without the pigmentation effects associated with full-length α-MSH. [1][2]

The peptide functions by modulating inflammatory pathways, particularly through inhibition of pro-inflammatory cytokines and regulation of NF-κB signaling. Research has demonstrated its ability to reduce inflammation in various tissue types, with particular interest in gastrointestinal applications for inflammatory bowel disease. [3][4]

KPV can be administered orally, topically, or via injection, with each route showing different tissue targeting properties. The oral route appears particularly promising for gut-targeted anti-inflammatory effects, while topical application may benefit skin conditions. Research remains largely preclinical, with human clinical trials still limited. [5][6]

Anti-Inflammatory Properties

• Inhibits NF-κB inflammatory pathway [1]
• Reduces pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) [2]
• Modulates immune cell activity [3]
• Exhibits anti-inflammatory effects without immunosuppression [4]

Gastrointestinal Health (Research Stage)

• Shows promise for inflammatory bowel disease (IBD) in animal models [5]
• May reduce colitis symptoms in preclinical studies [6]
• Protects intestinal barrier function [7]
• Oral administration targets gut inflammation [8]

Wound Healing and Skin Health

• Accelerates wound healing in animal models [9]
• Reduces skin inflammation [10]
• May benefit inflammatory skin conditions [11]

Antimicrobial Properties

• Demonstrates antimicrobial activity against certain bacteria [12]
• May support immune defense mechanisms [13]

Advantages:

• Targeted anti-inflammatory action [1]
• Multiple administration routes [5]
• Derived from natural peptide sequence [2]
• Does not cause pigmentation like full α-MSH [14]

Research Status:

• Primarily preclinical research stage [1]
• Limited human clinical trial data
• Not FDA-approved for any indication
• Considered a research peptide [2]

Preclinical Safety Observations:

• Generally well-tolerated in animal studies [3]
• No significant toxicity at studied doses [4]
• Minimal systemic side effects observed [5]

Potential Side Effects (Theoretical/Limited Data):

• Injection site reactions with subcutaneous use
• Gastrointestinal discomfort with oral administration
• Allergic reactions (possible but rare)
• Effects with long-term use unknown [6]

Current Limitations:

• Limited human safety data [1]
• Optimal dosing not established
• Long-term effects unknown
• Quality and purity vary among suppliers [7]
• Not regulated as pharmaceutical

Contraindications (Theoretical):

• Known allergies to the peptide or components
• Pregnancy and lactation (insufficient data)
• Individuals with immune disorders (use with caution) [8]

Drug Interactions:

• Potential interactions with immunomodulatory drugs unknown
• May interact with anti-inflammatory medications
• Interaction profile not well characterized [9]

Important Considerations:

• Most data from animal models and in vitro studies [3]
• Human efficacy not established
• Should be used only under medical supervision
• Quality control concerns with research-grade products [7]

Monitoring:

• If used experimentally, monitor for:
  • Allergic reactions
  • Changes in inflammatory markers
  • Gastrointestinal symptoms
  • Infection susceptibility [10]